| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.711 | 0.005 | 0.909 | Anticonvulsant | 0.813 0.004 DBMET03610 0.85 0.004 DBMET02277 0.909 0.003 DBMET03609 0.701 0.005 DBMET02278 0.806 0.004 DBMET03608 | DBMET03609 | |
| 0.643 | 0.003 | 0.743 | GABA A receptor antagonist | 0.691 0.003 DBMET03610 0.696 0.003 DBMET02277 0.743 0.002 DBMET03609 0.417 0.004 DBMET02278 0.466 0.003 DBMET03608 | DBMET03609 | |
| 0.636 | 0.003 | 0.747 | GABA receptor antagonist | 0.686 0.003 DBMET03610 0.699 0.003 DBMET02277 0.747 0.003 DBMET03609 0.411 0.004 DBMET02278 0.456 0.004 DBMET03608 | DBMET03609 | |
| 0.59 | 0.009 | 0.711 | GABA C receptor rho-3 antagonist | 0.359 0.081 DBMET03610 0.711 0.003 DBMET02277 0.546 0.015 DBMET03609 0.583 0.009 DBMET02278 0.349 0.087 DBMET03608 | DBMET02277 | |
| 0.564 | 0.002 | 0.618 | Benzodiazepine agonist | 0.618 0.002 DBMET03610 0.509 0.002 DBMET02277 0.575 0.002 DBMET03609 0.254 0.004 DBMET02278 0.315 0.003 DBMET03608 | DBMET03610 | |
| 0.56 | 0.005 | 0.56 | Sigma receptor agonist | 0.551 0.005 DBMET02277 0.448 0.015 DBMET02278 | ||
| 0.446 | 0.005 | 0.446 | Glutamate receptor antagonist | 0.172 0.037 DBMET03610 0.429 0.005 DBMET02277 0.152 0.05 DBMET03609 0.318 0.009 DBMET02278 | ||
| 0.463 | 0.028 | 0.463 | Aryl hydrocarbon receptor agonist | 0.348 0.048 DBMET03610 0.41 0.036 DBMET02277 0.303 0.06 DBMET03609 0.369 0.044 DBMET02278 0.267 0.072 DBMET03608 | ||
| 0.455 | 0.048 | 0.455 | Calcium channel L-type activator | 0.313 0.146 DBMET03610 0.429 0.062 DBMET02277 0.262 0.193 DBMET03609 0.383 0.093 DBMET02278 | ||
| 0.387 | 0.004 | 0.613 | GABA receptor agonist | 0.542 0.004 DBMET03610 0.461 0.004 DBMET02277 0.613 0.003 DBMET03609 0.343 0.005 DBMET02278 0.503 0.004 DBMET03608 | DBMET03609 | |
| 0.39 | 0.028 | 0.39 | Calcium channel activator | 0.243 0.156 DBMET03610 0.297 0.095 DBMET02277 | ||
| 0.377 | 0.02 | 0.377 | Cyclic AMP phosphodiesterase inhibitor | 0.355 0.024 DBMET02277 0.254 0.062 DBMET03611 0.292 0.045 DBMET02278 | ||
| 0.37 | 0.021 | 0.683 | Anesthetic general | 0.6 0.004 DBMET03610 0.467 0.01 DBMET02277 0.473 0.01 DBMET03611 0.683 0.004 DBMET03609 0.364 0.022 DBMET02278 0.594 0.005 DBMET03608 | DBMET03609 | |
| 0.37 | 0.028 | 0.521 | Psychostimulant | 0.365 0.029 DBMET03610 0.521 0.009 DBMET02277 0.203 0.078 DBMET03611 0.516 0.009 DBMET03609 0.38 0.026 DBMET02278 0.375 0.027 DBMET03608 | DBMET02277 | |
| 0.326 | 0.002 | 0.326 | Purinergic P2X4 antagonist | 0.075 0.008 DBMET03610 0.154 0.004 DBMET02277 0.046 0.031 DBMET03609 0.231 0.003 DBMET02278 0.059 0.015 DBMET03608 | ||
| 0.328 | 0.013 | 0.328 | Glycogen synthase kinase-3 alpha inhibitor | 0.143 0.071 DBMET03610 0.263 0.024 DBMET02277 0.198 0.042 DBMET02278 | ||
| 0.329 | 0.029 | 0.406 | Platelet aggregation inhibitor | 0.406 0.018 DBMET02277 0.35 0.026 DBMET02278 | DBMET02277 | |
| 0.315 | 0.032 | 0.407 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.221 0.063 DBMET03610 0.407 0.014 DBMET02277 0.326 0.029 DBMET03609 0.322 0.03 DBMET02278 0.235 0.057 DBMET03608 | DBMET02277 | |
| 0.386 | 0.113 | 0.459 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.296 0.219 DBMET03610 0.429 0.077 DBMET02277 0.341 0.161 DBMET03609 0.459 0.056 DBMET02278 0.374 0.125 DBMET03608 | DBMET02278 | |
| 0.281 | 0.017 | 0.281 | Nitric-oxide synthase stimulant | 0.248 0.034 DBMET03610 0.215 0.067 DBMET02277 0.254 0.03 DBMET03611 0.186 0.114 DBMET03609 0.174 0.142 DBMET02278 | ||
| 0.256 | 0.009 | 0.256 | NMDA receptor antagonist | 0.164 0.02 DBMET03610 0.198 0.014 DBMET02277 0.128 0.032 DBMET03609 0.118 0.036 DBMET02278 0.076 0.07 DBMET03608 | ||
| 0.289 | 0.054 | 0.396 | Interleukin agonist | 0.364 0.025 DBMET02277 0.288 0.054 DBMET03611 0.205 0.116 DBMET03609 0.396 0.019 DBMET02278 0.234 0.091 DBMET03608 | DBMET02278 | |
| 0.307 | 0.076 | 0.307 | 12-Lipoxygenase inhibitor | 0.223 0.128 DBMET02277 0.221 0.13 DBMET02278 | ||
| 0.333 | 0.106 | 0.356 | MAP kinase kinase 6 inhibitor | 0.269 0.168 DBMET03610 0.356 0.088 DBMET02277 0.292 0.144 DBMET03609 0.247 0.194 DBMET02278 | DBMET02277 | |
| 0.23 | 0.006 | 0.23 | Glutamate (mGluR group I) antagonist | 0.188 0.009 DBMET02277 0.149 0.014 DBMET02278 | ||
| 0.238 | 0.016 | 0.307 | Death-associated protein kinase 2 inhibitor | 0.233 0.018 DBMET03610 0.238 0.016 DBMET02277 0.233 0.018 DBMET03609 0.307 0.006 DBMET02278 0.295 0.007 DBMET03608 | DBMET02278 | |
| 0.226 | 0.006 | 0.397 | Potassium channel activator | 0.397 0.004 DBMET03610 0.143 0.023 DBMET02277 0.249 0.005 DBMET03609 0.182 0.012 DBMET02278 0.322 0.004 DBMET03608 | DBMET03610 | |
| 0.234 | 0.015 | 0.355 | GABA C receptor rho-2 antagonist | 0.145 0.08 DBMET03610 0.355 0.004 DBMET02277 0.223 0.019 DBMET03609 0.226 0.018 DBMET02278 0.14 0.088 DBMET03608 | DBMET02277 | |
| 0.221 | 0.004 | 0.221 | NMDA receptor subunit 3B antagonist | 0.107 0.01 DBMET03610 0.128 0.008 DBMET02277 0.05 0.025 DBMET03609 0.06 0.019 DBMET02278 | ||
| 0.244 | 0.038 | 0.244 | Mcl-1 antagonist | 0.137 0.104 DBMET02277 0.129 0.113 DBMET02278 | ||
| 0.216 | 0.009 | 0.235 | Interleukin 8 antagonist | 0.235 0.007 DBMET03610 0.204 0.012 DBMET02277 0.102 0.092 DBMET03611 0.221 0.009 DBMET03609 0.147 0.036 DBMET02278 0.162 0.027 DBMET03608 | DBMET03610 | |
| 0.208 | 0.009 | 0.208 | Glutamate (mGluR) antagonist | 0.184 0.012 DBMET02277 0.125 0.024 DBMET02278 | ||
| 0.196 | 0.004 | 0.196 | AMPA receptor antagonist | 0.157 0.005 DBMET03610 0.136 0.007 DBMET02277 0.107 0.01 DBMET03609 | ||
| 0.203 | 0.012 | 0.394 | GABA C receptor antagonist | 0.394 0.003 DBMET02277 0.177 0.019 DBMET03609 0.192 0.014 DBMET02278 | DBMET02277 | |
| 0.199 | 0.015 | 0.199 | Falcipain inhibitor | 0.19 0.017 DBMET02277 0.191 0.017 DBMET02278 | ||
| 0.198 | 0.014 | 0.198 | Falcipain 2 inhibitor | 0.188 0.016 DBMET02277 0.188 0.016 DBMET02278 | ||
| 0.255 | 0.077 | 0.28 | DNA damaging | 0.28 0.066 DBMET03610 0.196 0.119 DBMET02277 0.252 0.079 DBMET03611 0.217 0.102 DBMET03609 | DBMET03610 | |
| 0.253 | 0.076 | 0.292 | Gastrin inhibitor | 0.256 0.072 DBMET02277 0.292 0.039 DBMET02278 | DBMET02278 | |
| 0.226 | 0.051 | 0.332 | LIM domain kinase 1 inhibitor | 0.332 0.015 DBMET02277 0.218 0.054 DBMET03609 0.279 0.026 DBMET02278 0.163 0.086 DBMET03608 | DBMET02277 | |
| 0.195 | 0.027 | 0.273 | Platelet activating factor antagonist | 0.273 0.014 DBMET02277 0.098 0.08 DBMET03609 0.221 0.021 DBMET02278 | DBMET02277 | |
| 0.209 | 0.044 | 0.209 | Heat shock protein 90 alpha antagonist | 0.142 0.096 DBMET03610 0.147 0.089 DBMET02277 0.128 0.114 DBMET02278 | ||
| 0.261 | 0.096 | 0.439 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.387 0.024 DBMET03610 0.32 0.051 DBMET02277 0.439 0.014 DBMET03609 0.271 0.087 DBMET02278 0.386 0.025 DBMET03608 | DBMET03609 | |
| 0.189 | 0.038 | 0.189 | Alkaline phosphatase inhibitor | 0.157 0.055 DBMET03610 0.123 0.082 DBMET02277 0.179 0.042 DBMET03611 | ||
| 0.146 | 0.003 | 0.146 | NMDA receptor glycine site antagonist | 0.084 0.004 DBMET03610 0.064 0.005 DBMET02277 0.04 0.008 DBMET03609 0.075 0.004 DBMET02278 0.045 0.007 DBMET03608 | ||
| 0.149 | 0.014 | 0.2 | Cyclin B3 inhibitor | 0.187 0.008 DBMET03610 0.165 0.01 DBMET02277 0.2 0.006 DBMET03609 0.13 0.018 DBMET02278 0.171 0.01 DBMET03608 | DBMET03609 | |
| 0.139 | 0.005 | 0.139 | NMDA receptor subunit 3A antagonist | 0.059 0.017 DBMET03610 0.096 0.009 DBMET02277 0.036 0.028 DBMET03609 0.035 0.029 DBMET02278 | ||
| 0.213 | 0.082 | 0.243 | RNA-directed DNA polymerase inhibitor | 0.196 0.106 DBMET03610 0.243 0.054 DBMET02277 0.199 0.101 DBMET03611 0.224 0.069 DBMET03609 | DBMET02277 | |
| 0.136 | 0.005 | 0.136 | GABA B receptor agonist | 0.114 0.009 DBMET03610 0.098 0.018 DBMET02277 0.085 0.033 DBMET03609 0.088 0.028 DBMET02278 0.076 0.051 DBMET03608 | ||
| 0.154 | 0.026 | 0.154 | Potassium channel (Ca-activated) activator | 0.088 0.066 DBMET03610 0.106 0.051 DBMET02277 | ||
| 0.133 | 0.006 | 0.143 | NMDA receptor glycine site agonist | 0.114 0.011 DBMET03610 0.126 0.007 DBMET02277 0.108 0.013 DBMET03609 0.143 0.005 DBMET02278 0.123 0.008 DBMET03608 | DBMET02278 | |
| 0.129 | 0.004 | 0.129 | Kainate receptor 2 antagonist | 0.092 0.005 DBMET03610 0.064 0.01 DBMET02277 0.039 0.022 DBMET03609 0.032 0.028 DBMET02278 | ||
| 0.225 | 0.103 | 0.225 | 5 Hydroxytryptamine 1E antagonist | 0.19 0.143 DBMET02278 | ||
| 0.198 | 0.076 | 0.316 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.316 0.039 DBMET02277 0.197 0.077 DBMET03609 0.186 0.084 DBMET02278 | DBMET02277 | |
| 0.126 | 0.004 | 0.126 | GABA B receptor antagonist | 0.047 0.023 DBMET03610 0.083 0.006 DBMET02277 | ||
| 0.13 | 0.009 | 0.13 | NMDA 2C receptor antagonist | 0.081 0.024 DBMET03610 0.1 0.016 DBMET02277 0.063 0.041 DBMET03609 0.058 0.048 DBMET02278 | ||
| 0.144 | 0.026 | 0.146 | DNA directed RNA polymerase inhibitor | 0.146 0.025 DBMET02277 0.104 0.052 DBMET02278 | DBMET02277 | |
| 0.122 | 0.005 | 0.194 | Kainate receptor antagonist | 0.194 0.004 DBMET03610 0.081 0.01 DBMET02277 0.135 0.005 DBMET03609 0.036 0.032 DBMET03608 | DBMET03610 | |
| 0.152 | 0.035 | 0.205 | Polo-like kinase-4 inhibitor | 0.205 0.014 DBMET02277 0.095 0.082 DBMET03609 0.173 0.024 DBMET02278 | DBMET02277 | |
| 0.122 | 0.01 | 0.122 | Glutamate (mGluR1) antagonist | 0.058 0.041 DBMET02277 | ||
| 0.15 | 0.043 | 0.151 | DNA intercalator | 0.106 0.068 DBMET03610 0.114 0.061 DBMET02277 0.151 0.042 DBMET03611 | DBMET03611 | |
| 0.114 | 0.008 | 0.14 | Phosphodiesterase II inhibitor | 0.14 0.005 DBMET02277 0.104 0.01 DBMET02278 | DBMET02277 | |
| 0.192 | 0.087 | 0.349 | MAP kinase kinase 2 inhibitor | 0.349 0.021 DBMET02277 0.266 0.047 DBMET03609 0.242 0.058 DBMET02278 0.158 0.114 DBMET03608 | DBMET02277 | |
| 0.107 | 0.004 | 0.144 | Benzodiazepine antagonist | 0.084 0.005 DBMET03610 0.111 0.004 DBMET02277 0.086 0.004 DBMET03609 0.144 0.003 DBMET02278 0.108 0.004 DBMET03608 | DBMET02278 | |
| 0.16 | 0.061 | 0.16 | Thiol protease inhibitor | 0.123 0.11 DBMET02277 0.122 0.112 DBMET02278 | ||
| 0.13 | 0.032 | 0.242 | GABA C receptor rho-1 antagonist | 0.242 0.005 DBMET02277 0.137 0.028 DBMET03609 0.124 0.036 DBMET02278 | DBMET02277 | |
| 0.112 | 0.015 | 0.119 | NMDA receptor agonist | 0.089 0.024 DBMET03610 0.109 0.016 DBMET02277 0.086 0.025 DBMET03609 0.119 0.013 DBMET02278 0.096 0.021 DBMET03608 | DBMET02278 | |
| 0.156 | 0.059 | 0.156 | Toll-Like receptor 9 antagonist | 0.112 0.096 DBMET02277 | ||
| 0.106 | 0.009 | 0.11 | Glutamate (mGluR5) antagonist | 0.11 0.009 DBMET02277 0.088 0.012 DBMET02278 | DBMET02277 | |
| 0.105 | 0.008 | 0.13 | Phosphodiesterase 2A inhibitor | 0.13 0.005 DBMET02277 0.094 0.01 DBMET02278 | DBMET02277 | |
| 0.15 | 0.054 | 0.15 | NADPH oxidase inhibitor | 0.123 0.079 DBMET02277 | ||
| 0.149 | 0.054 | 0.149 | Pregnane X receptor agonist | 0.149 0.055 DBMET02278 | ||
| 0.217 | 0.123 | 0.217 | Streptokinase A inhibitor | |||
| 0.152 | 0.063 | 0.165 | Mannose-6-phosphate isomerase inhibitor | 0.129 0.087 DBMET03610 0.165 0.053 DBMET03611 | DBMET03611 | |
| 0.098 | 0.012 | 0.103 | Phosphodiesterase 3B inhibitor | 0.103 0.01 DBMET02277 0.076 0.015 DBMET02278 | DBMET02277 | |
| 0.094 | 0.009 | 0.094 | MDM2 inhibitor | 0.064 0.058 DBMET03610 0.073 0.031 DBMET02277 | ||
| 0.14 | 0.057 | 0.15 | Death-associated protein kinase 1 inhibitor | 0.132 0.075 DBMET03610 0.129 0.085 DBMET02277 0.122 0.107 DBMET03609 0.15 0.039 DBMET02278 0.142 0.053 DBMET03608 | DBMET02278 | |
| 0.154 | 0.071 | 0.154 | Heat shock protein 90 antagonist | 0.137 0.088 DBMET02277 | ||
| 0.187 | 0.105 | 0.331 | ErbB-1 antagonist | 0.331 0.026 DBMET02277 0.265 0.045 DBMET03609 0.244 0.054 DBMET02278 0.199 0.09 DBMET03608 | DBMET02277 | |
| 0.124 | 0.042 | 0.437 | Beta glucuronidase inhibitor | 0.177 0.016 DBMET03610 0.437 0.004 DBMET03611 0.098 0.073 DBMET03609 0.096 0.076 DBMET03608 | DBMET03611 | |
| 0.106 | 0.027 | 0.128 | Glycine receptor antagonist | 0.096 0.036 DBMET03610 0.081 0.055 DBMET02277 0.128 0.014 DBMET03611 0.072 0.071 DBMET03609 0.117 0.02 DBMET02278 0.106 0.027 DBMET03608 | DBMET03611 | |
| 0.162 | 0.083 | 0.162 | 3C-like protease (Human coronavirus) inhibitor | |||
| 0.104 | 0.025 | 0.104 | Prostaglandin-E synthase inhibitor | 0.083 0.037 DBMET02278 | ||
| 0.18 | 0.106 | 0.218 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.218 0.082 DBMET02277 0.154 0.128 DBMET02278 | DBMET02277 | |
| 0.096 | 0.025 | 0.096 | Phosphodiesterase III inhibitor | 0.088 0.029 DBMET02277 0.069 0.044 DBMET02278 | ||
| 0.254 | 0.184 | 0.254 | Transcription factor inhibitor | |||
| 0.077 | 0.007 | 0.077 | AMPA 1 receptor antagonist | 0.047 0.012 DBMET03610 0.03 0.02 DBMET02277 | ||
| 0.1 | 0.032 | 0.1 | Phosphodiesterase 3A inhibitor | 0.092 0.04 DBMET02277 0.077 0.061 DBMET02278 | ||
| 0.127 | 0.061 | 0.127 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.112 | 0.047 | 0.138 | Hedgehog signaling inhibitor | 0.132 0.032 DBMET02277 0.138 0.029 DBMET02278 | DBMET02278 | |
| 0.155 | 0.09 | 0.155 | Neurotensin receptor agonist | |||
| 0.085 | 0.021 | 0.086 | Phosphodiesterase VII inhibitor | 0.086 0.021 DBMET02277 0.064 0.042 DBMET02278 | DBMET02277 | |
| 0.175 | 0.114 | 0.228 | Dyrk kinase inhibitor | 0.228 0.083 DBMET02277 0.154 0.132 DBMET02278 | DBMET02277 | |
| 0.095 | 0.036 | 0.098 | D-Ala-D-Ala ligase inhibitor | 0.098 0.032 DBMET03610 0.094 0.038 DBMET02277 0.097 0.033 DBMET03609 | DBMET03610 | |
| 0.078 | 0.019 | 0.099 | Corticotropin releasing factor 2 receptor antagonist | 0.099 0.007 DBMET02277 0.094 0.009 DBMET02278 | DBMET02277 | |
| 0.081 | 0.023 | 0.081 | Androgen agonist | 0.07 0.03 DBMET03610 | ||
| 0.162 | 0.106 | 0.195 | Death-associated protein kinase 3 inhibitor | 0.195 0.077 DBMET02277 0.153 0.117 DBMET03609 0.167 0.1 DBMET02278 | DBMET02277 | |
| 0.075 | 0.021 | 0.075 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.059 | 0.005 | 0.059 | Kainate receptor 1 antagonist | 0.034 0.009 DBMET03610 | ||
| 0.114 | 0.061 | 0.15 | EphA2 antagonist | 0.15 0.03 DBMET02277 0.128 0.047 DBMET02278 | DBMET02277 | |
| 0.058 | 0.005 | 0.192 | Benzodiazepine receptor peripheral-type antagonist | 0.186 0.002 DBMET03610 0.06 0.005 DBMET02277 0.079 0.004 DBMET03611 0.192 0.002 DBMET03609 0.066 0.004 DBMET02278 0.189 0.002 DBMET03608 | DBMET03609 | |
| 0.074 | 0.022 | 0.075 | NMDA 2A receptor antagonist | 0.075 0.022 DBMET02277 | DBMET02277 | |
| 0.082 | 0.03 | 0.082 | Bcl2 antagonist | |||
| 0.17 | 0.121 | 0.17 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | |||
| 0.064 | 0.016 | 0.076 | Sodium/calcium exchanger inhibitor | 0.076 0.01 DBMET02277 0.047 0.043 DBMET03609 0.047 0.043 DBMET02278 | DBMET02277 | |
| 0.095 | 0.047 | 0.095 | Interleukin 5 antagonist | 0.082 0.068 DBMET03610 0.086 0.06 DBMET03611 | ||
| 0.087 | 0.039 | 0.087 | NMDA 2 receptor antagonist | 0.074 0.048 DBMET02277 | ||
| 0.15 | 0.105 | 0.171 | Catenin beta inhibitor | 0.171 0.065 DBMET02277 0.154 0.096 DBMET03609 0.149 0.109 DBMET02278 | DBMET02277 | |
| 0.1 | 0.055 | 0.137 | HIV-1 integrase (Overall Integration) inhibitor | 0.137 0.03 DBMET02277 | DBMET02277 | |
| 0.059 | 0.015 | 0.059 | Benzodiazepine inverse agonist | 0.053 0.021 DBMET02277 0.048 0.028 DBMET02278 | ||
| 0.05 | 0.007 | 0.05 | Kainate receptor 4 antagonist | 0.043 0.009 DBMET03610 | ||
| 0.094 | 0.051 | 0.094 | Androgen antagonist | |||
| 0.058 | 0.016 | 0.066 | CDK5/p25 inhibitor | 0.051 0.02 DBMET02277 0.066 0.013 DBMET02278 0.036 0.035 DBMET03608 | DBMET02278 | |
| 0.137 | 0.099 | 0.151 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.151 0.071 DBMET02277 0.139 0.094 DBMET03609 0.13 0.116 DBMET02278 | DBMET02277 | |
| 0.139 | 0.104 | 0.139 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | |||
| 0.105 | 0.07 | 0.105 | Alpha 2b adrenoreceptor antagonist | 0.088 0.087 DBMET02277 | ||
| 0.096 | 0.062 | 0.096 | Phosphodiesterase 7B inhibitor | |||
| 0.104 | 0.071 | 0.187 | Protein kinase C gamma inhibitor | 0.148 0.033 DBMET03610 0.137 0.04 DBMET02277 0.187 0.017 DBMET03609 0.12 0.053 DBMET03608 | DBMET03609 | |
| 0.066 | 0.034 | 0.094 | Cyclin D1 inhibitor | 0.094 0.01 DBMET02277 0.076 0.022 DBMET03609 0.087 0.013 DBMET02278 0.069 0.03 DBMET03608 | DBMET02277 | |
| 0.072 | 0.042 | 0.072 | Potassium channel large-conductance Ca-activated activator | |||
| 0.051 | 0.024 | 0.088 | Cholecystokinin antagonist | 0.065 0.016 DBMET03610 0.059 0.019 DBMET02277 0.073 0.013 DBMET03609 0.072 0.014 DBMET02278 0.088 0.01 DBMET03608 | DBMET03608 | |
| 0.042 | 0.018 | 0.042 | Integrin alpha2 antagonist | 0.035 0.029 DBMET03610 0.035 0.029 DBMET02277 | ||
| 0.045 | 0.021 | 0.076 | Cholecystokinin A antagonist | 0.058 0.017 DBMET02277 0.076 0.013 DBMET02278 | DBMET02278 | |
| 0.032 | 0.009 | 0.032 | Kainate receptor 5 antagonist | 0.026 0.011 DBMET03610 | ||
| 0.121 | 0.1 | 0.207 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.207 0.048 DBMET02277 0.146 0.08 DBMET03609 0.15 0.077 DBMET02278 | DBMET02277 | |
| 0.095 | 0.073 | 0.095 | Urease inhibitor | |||
| 0.053 | 0.033 | 0.053 | Phosphodiesterase 7A inhibitor | 0.052 0.035 DBMET02277 | ||
| 0.111 | 0.093 | 0.183 | DNA repair enzyme inhibitor | 0.113 0.088 DBMET02277 0.183 0.013 DBMET03611 | DBMET03611 | |
| 0.048 | 0.03 | 0.06 | Thymidylate synthase inhibitor | 0.06 0.017 DBMET03610 0.043 0.037 DBMET02277 0.055 0.021 DBMET03609 | DBMET03610 | |
| 0.042 | 0.024 | 0.042 | AMPA 4 receptor antagonist | 0.037 0.033 DBMET02277 | ||
| 0.098 | 0.081 | 0.098 | Glycogen synthase kinase-3 inhibitor | 0.096 0.083 DBMET02277 | ||
| 0.185 | 0.168 | 0.201 | Thyroid hormone beta antagonist | 0.201 0.153 DBMET02278 | DBMET02278 | |
| 0.058 | 0.041 | 0.058 | Botulinum neurotoxin type A inhibitor | |||
| 0.034 | 0.017 | 0.034 | AMPA 3 receptor antagonist | |||
| 0.125 | 0.109 | 0.188 | Cyclin-dependent kinase 8 inhibitor | 0.188 0.044 DBMET02277 0.172 0.059 DBMET02278 | DBMET02277 | |
| 0.079 | 0.063 | 0.079 | Thioredoxin reductase inhibitor | |||
| 0.023 | 0.007 | 0.023 | Kainate receptor 3 antagonist | 0.02 0.009 DBMET03610 | ||
| 0.032 | 0.017 | 0.081 | Cyclin E2 inhibitor | 0.043 0.011 DBMET03610 0.049 0.009 DBMET02277 0.063 0.006 DBMET03609 0.062 0.006 DBMET02278 0.081 0.005 DBMET03608 | DBMET03608 | |
| 0.041 | 0.026 | 0.041 | Phenylethanolamine N methyltransferase inhibitor | |||
| 0.102 | 0.087 | 0.115 | Interleukin 2 antagonist | 0.106 0.075 DBMET02277 0.115 0.054 DBMET02278 | DBMET02278 | |
| 0.086 | 0.072 | 0.148 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.101 0.053 DBMET03610 0.148 0.027 DBMET03611 | DBMET03611 | |
| 0.097 | 0.084 | 0.109 | Multidrug resistance-associated protein 1 inhibitor | 0.109 0.063 DBMET03611 | DBMET03611 | |
| 0.052 | 0.039 | 0.052 | Nicotinic alpha3beta2 receptor antagonist | |||
| 0.029 | 0.017 | 0.029 | NMDA 2D receptor antagonist | 0.025 0.022 DBMET03610 | ||
| 0.124 | 0.113 | 0.141 | Neuropeptide Y1 antagonist | 0.141 0.08 DBMET02277 0.135 0.091 DBMET02278 | DBMET02277 | |
| 0.11 | 0.099 | 0.11 | Calcium channel blocker | |||
| 0.086 | 0.076 | 0.145 | MAP kinase kinase 1 inhibitor | 0.145 0.018 DBMET02277 0.112 0.043 DBMET03609 0.096 0.061 DBMET02278 | DBMET02277 | |
| 0.088 | 0.079 | 0.097 | Cyclin-dependent kinase 9 inhibitor | 0.097 0.066 DBMET02277 | DBMET02277 | |
| 0.052 | 0.043 | 0.074 | Cyclin B2 inhibitor | 0.067 0.024 DBMET03610 0.06 0.032 DBMET02277 0.074 0.019 DBMET03609 0.055 0.039 DBMET02278 0.068 0.023 DBMET03608 | DBMET03609 | |
| 0.043 | 0.035 | 0.149 | Phosphorylase inhibitor | 0.047 0.032 DBMET03610 0.041 0.036 DBMET02277 0.149 0.007 DBMET03611 0.046 0.033 DBMET03609 | DBMET03611 | |
| 0.038 | 0.031 | 0.048 | Acid-sensing ion channel blocker | 0.048 0.018 DBMET02277 | DBMET02277 | |
| 0.041 | 0.034 | 0.041 | Nerve growth factor antagonist | |||
| 0.085 | 0.079 | 0.085 | Creatine kinase inhibitor | |||
| 0.086 | 0.08 | 0.28 | UDP-glucose 4-epimerase inhibitor | 0.109 0.051 DBMET03610 0.28 0.011 DBMET03611 | DBMET03611 | |
| 0.124 | 0.119 | 0.189 | Polo-like kinase-3 inhibitor | 0.189 0.051 DBMET02277 0.147 0.087 DBMET02278 | DBMET02277 | |
| 0.052 | 0.047 | 0.052 | Fatty acid synthase inhibitor | |||
| 0.09 | 0.085 | 0.127 | Cyclin-dependent kinase 5 inhibitor | 0.088 0.086 DBMET03610 0.101 0.074 DBMET02277 0.099 0.076 DBMET03609 0.127 0.053 DBMET02278 0.122 0.057 DBMET03608 | DBMET02278 | |
| 0.08 | 0.077 | 0.121 | Bromodomain-containing protein 2 inhibitor | 0.114 0.027 DBMET02277 0.121 0.022 DBMET02278 | DBMET02278 | |
| 0.103 | 0.101 | 0.103 | Cathepsin H inhibitor | |||
| 0.08 | 0.077 | 0.13 | Pim-3 kinase inhibitor | 0.13 0.026 DBMET02277 0.092 0.055 DBMET03609 | DBMET02277 | |
| 0.024 | 0.023 | 0.024 | Integrin alpha2beta1 antagonist | |||
| 0.053 | 0.052 | 0.076 | Cyclin B1 inhibitor | 0.07 0.032 DBMET03610 0.062 0.042 DBMET02277 0.076 0.026 DBMET03609 0.056 0.049 DBMET02278 0.07 0.031 DBMET03608 | DBMET03609 | |
| 0.049 | 0.048 | 0.068 | Cyclin B inhibitor | 0.063 0.028 DBMET03610 0.054 0.04 DBMET02277 0.068 0.023 DBMET03609 0.049 0.048 DBMET02278 0.063 0.028 DBMET03608 | DBMET03609 | |
| 0.179 | 0.18 | 0.188 | Thyroid hormone antagonist | 0.188 0.172 DBMET02278 | DBMET02278 | |
| 0.25 | 0.253 | 0.384 | Caspase 9 stimulant | 0.303 0.19 DBMET03610 0.384 0.121 DBMET03611 | DBMET03611 | |
| 0.096 | 0.104 | 0.147 | MAP kinase 12 inhibitor | 0.147 0.043 DBMET02277 0.136 0.053 DBMET03609 0.117 0.073 DBMET02278 0.11 0.083 DBMET03608 | DBMET02277 | |
| 0.134 | 0.143 | 0.182 | Cyclin-dependent kinase 3 inhibitor | 0.141 0.12 DBMET02277 0.182 0.047 DBMET02278 0.172 0.058 DBMET03608 | DBMET02278 | |
| 0.124 | 0.137 | 0.211 | Interleukin 6 antagonist | 0.188 0.048 DBMET03610 0.145 0.097 DBMET02277 0.198 0.042 DBMET03611 0.211 0.035 DBMET03609 0.132 0.121 DBMET03608 | DBMET03609 | |
| 0.226 | 0.241 | 0.386 | Apoptosis agonist | 0.386 0.121 DBMET03611 | DBMET03611 | |
| 0.112 | 0.128 | 0.364 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.21 0.06 DBMET03610 0.243 0.047 DBMET02277 0.364 0.024 DBMET03609 0.136 0.099 DBMET02278 0.236 0.049 DBMET03608 | DBMET03609 | |
| 0.05 | 0.069 | 0.088 | 5 Hydroxytryptamine 5A antagonist | 0.088 0.019 DBMET02277 | DBMET02277 | |
| 0.047 | 0.067 | 0.071 | Cannabinoid CB1 receptor antagonist | 0.055 0.051 DBMET02277 0.071 0.034 DBMET02278 | DBMET02278 | |
| 0.077 | 0.098 | 0.089 | Lanosterol 14 alpha demethylase inhibitor | 0.089 0.074 DBMET02277 | DBMET02277 | |
| 0.088 | 0.11 | 0.188 | MAP kinase kinase inhibitor | 0.188 0.033 DBMET02277 0.107 0.087 DBMET02278 | DBMET02277 | |
| 0.049 | 0.071 | 0.058 | Potassium channel (Ca-activated) blocker | 0.058 0.045 DBMET02277 | DBMET02277 | |
| 0.061 | 0.084 | 0.087 | Platelet growth factor antagonist | 0.087 0.05 DBMET02277 0.073 0.064 DBMET02278 | DBMET02277 | |
| 0.167 | 0.189 | 0.243 | Neuropeptide Y2 antagonist | 0.192 0.134 DBMET02277 0.243 0.063 DBMET02278 0.18 0.159 DBMET03608 | DBMET02278 | |
| 0.071 | 0.096 | 0.122 | Triose-phosphate isomerase inhibitor | 0.122 0.031 DBMET03611 | DBMET03611 | |
| 0.023 | 0.049 | 0.03 | Catechol O-methyltransferase inhibitor | 0.03 0.027 DBMET03610 | DBMET03610 | |
| 0.05 | 0.077 | 0.066 | CDC7 inhibitor | 0.066 0.049 DBMET02277 | DBMET02277 | |
| 0.082 | 0.111 | 0.094 | Nav1.4 sodium channel blocker | 0.093 0.087 DBMET02277 0.094 0.086 DBMET02278 | DBMET02278 | |
| 0.099 | 0.128 | 0.137 | Activin receptor-like kinase 2 inhibitor | 0.137 0.078 DBMET02277 | DBMET02277 | |
| 0.116 | 0.148 | 0.137 | MAP kinase 3 inhibitor | 0.134 0.097 DBMET03610 0.137 0.091 DBMET03609 0.132 0.101 DBMET03608 | DBMET03609 | |
| 0.065 | 0.098 | 0.091 | GABA A receptor agonist | 0.091 0.047 DBMET02277 0.082 0.06 DBMET02278 | DBMET02277 | |
| 0.068 | 0.101 | 0.092 | Protein kinase (CK2) inhibitor | 0.092 0.071 DBMET02278 | DBMET02278 | |
| 0.053 | 0.087 | 0.066 | Kallikrein 7 inhibitor | 0.064 0.043 DBMET02278 0.066 0.036 DBMET03608 | DBMET03608 | |
| 0.084 | 0.118 | 0.112 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.112 0.089 DBMET02277 | DBMET02277 | |
| 0.168 | 0.202 | 0.268 | Thioredoxin glutathione reductase inhibitor | 0.268 0.123 DBMET03610 | DBMET03610 | |
| 0.124 | 0.158 | 0.193 | ATPase inhibitor | 0.193 0.043 DBMET03611 0.162 0.083 DBMET02278 | DBMET03611 | |
| 0.034 | 0.069 | 0.06 | Cyclin E inhibitor | 0.059 0.042 DBMET02278 0.06 0.041 DBMET03608 | DBMET03608 | |
| 0.097 | 0.132 | 0.132 | Protein kinase (CK1) gamma 1 inhibitor | 0.132 0.085 DBMET02277 | DBMET02277 | |
| 0.044 | 0.079 | 0.075 | 5 Hydroxytryptamine 5 antagonist | 0.075 0.023 DBMET02277 | DBMET02277 | |
| 0.075 | 0.113 | 0.095 | Cyclin-dependent kinase 2 inhibitor | 0.095 0.075 DBMET02277 | DBMET02277 | |
| 0.079 | 0.119 | 0.09 | Adenylate kinase inhibitor | 0.09 0.088 DBMET03610 | DBMET03610 | |
| 0.092 | 0.136 | 0.129 | CDC-like kinase 1 inhibitor | 0.129 0.086 DBMET02277 | DBMET02277 | |
| 0.031 | 0.075 | 0.085 | Plasminogen activator inhibitor | 0.076 0.028 DBMET03610 0.084 0.023 DBMET03609 0.085 0.023 DBMET03608 | DBMET03608 | |
| 0.063 | 0.107 | 0.083 | Cyclin-dependent kinase 1 inhibitor | 0.083 0.08 DBMET03609 | DBMET03609 | |
| 0.052 | 0.098 | 0.084 | Protein kinase B gamma inhibitor | 0.082 0.045 DBMET02277 0.067 0.061 DBMET03609 0.084 0.043 DBMET02278 0.07 0.058 DBMET03608 | DBMET02278 | |
| 0.125 | 0.173 | 0.188 | Focal adhesion kinase 2 inhibitor | 0.188 0.079 DBMET02277 0.154 0.125 DBMET02278 | DBMET02277 | |
| 0.116 | 0.165 | 0.149 | MAP kinase kinase 4 inhibitor | 0.149 0.063 DBMET02277 0.144 0.074 DBMET03609 | DBMET02277 | |
| 0.076 | 0.125 | 0.138 | MAP kinase 13 inhibitor | 0.138 0.043 DBMET02277 0.125 0.051 DBMET03609 0.103 0.077 DBMET02278 0.097 0.086 DBMET03608 | DBMET02277 | |
| 0.01 | 0.06 | 0.042 | Cholecystokinin B antagonist | 0.031 0.021 DBMET03610 0.035 0.018 DBMET03609 0.042 0.013 DBMET03608 | DBMET03608 | |
| 0.042 | 0.092 | 0.092 | MAP kinase 11 inhibitor | 0.092 0.04 DBMET02277 | DBMET02277 | |
| 0.082 | 0.136 | 0.149 | CDK3/cyclin E inhibitor | 0.108 0.073 DBMET02277 0.149 0.027 DBMET02278 0.134 0.039 DBMET03608 | DBMET02278 | |
| 0.077 | 0.135 | 0.103 | Cyclin-dependent kinase 7 inhibitor | 0.103 0.098 DBMET02277 | DBMET02277 | |
| 0.06 | 0.12 | 0.175 | Topoisomerase I inhibitor | 0.175 0.033 DBMET03611 | DBMET03611 | |
| 0.124 | 0.191 | 0.176 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.176 0.099 DBMET02277 0.146 0.139 DBMET02278 | DBMET02277 | |
| 0.032 | 0.099 | 0.07 | Protein kinase C eta inhibitor | 0.055 0.038 DBMET03610 0.07 0.028 DBMET03609 0.048 0.047 DBMET03608 | DBMET03609 | |
| 0.064 | 0.132 | 0.116 | Protein kinase (CK2) alpha inhibitor | 0.116 0.065 DBMET02278 | DBMET02278 | |
| 0.039 | 0.108 | 0.063 | Cannabinoid receptor antagonist | 0.063 0.058 DBMET02278 | DBMET02278 | |
| 0.064 | 0.137 | 0.09 | Thioredoxin inhibitor | 0.09 0.062 DBMET03611 | DBMET03611 | |
| 0.018 | 0.092 | 0.032 | Factor XI inhibitor | 0.032 0.026 DBMET02278 | DBMET02278 | |
| 0.064 | 0.141 | 0.135 | 5 Hydroxytryptamine 3A agonist | 0.135 0.045 DBMET02277 | DBMET02277 | |
| 0.07 | 0.149 | 0.142 | Toll-Like receptor 4 antagonist | 0.142 0.026 DBMET03611 | DBMET03611 | |
| 0.088 | 0.167 | 0.23 | Cell wall synthesis inhibitor | 0.123 0.095 DBMET03610 0.23 0.02 DBMET03611 | DBMET03611 | |
| 0.02 | 0.102 | 0.04 | Factor XIa inhibitor | 0.04 0.029 DBMET02278 | DBMET02278 | |
| 0.029 | 0.115 | 0.059 | Cyclin A1 inhibitor | 0.059 0.04 DBMET02277 0.055 0.05 DBMET02278 | DBMET02277 | |
| 0.173 | 0.26 | 0.208 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.208 0.143 DBMET02277 | DBMET02277 | |
| 0.041 | 0.129 | 0.095 | Topoisomerase II alpha inhibitor | 0.095 0.043 DBMET03611 | DBMET03611 | |
| 0.062 | 0.152 | 0.236 | Protein kinase C zeta inhibitor | 0.082 0.081 DBMET03610 0.153 0.019 DBMET02277 0.236 0.008 DBMET03609 0.105 0.045 DBMET03608 | DBMET03609 | |
| 0.023 | 0.113 | 0.045 | Dihydroorotase inhibitor | 0.045 0.03 DBMET02278 | DBMET02278 | |
| 0.027 | 0.121 | 0.069 | Pim-2 kinase inhibitor | 0.069 0.025 DBMET02277 | DBMET02277 | |
| 0.019 | 0.114 | 0.045 | Adenosine A2b receptor antagonist | 0.045 0.04 DBMET02278 | DBMET02278 | |
| 0.092 | 0.187 | 0.201 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.201 0.076 DBMET02277 0.156 0.114 DBMET03609 0.171 0.1 DBMET02278 | DBMET02277 | |
| 0.078 | 0.175 | 0.236 | Peroxidase inhibitor | 0.229 0.052 DBMET02277 0.236 0.05 DBMET03609 | DBMET03609 | |
| 0.077 | 0.176 | 0.127 | Histone deacetylase SIRT1 inhibitor | 0.127 0.083 DBMET02278 | DBMET02278 | |
| 0.026 | 0.126 | 0.055 | 5 Hydroxytryptamine 6 antagonist | 0.055 0.041 DBMET02277 | DBMET02277 | |
| 0.096 | 0.196 | 0.192 | Interleukin antagonist | 0.192 0.089 DBMET02278 | DBMET02278 | |
| 0.087 | 0.188 | 0.152 | Clk dual-specificity kinase inhibitor | 0.152 0.112 DBMET02277 | DBMET02277 | |
| 0.054 | 0.158 | 0.114 | Topoisomerase II inhibitor | 0.114 0.072 DBMET03611 | DBMET03611 | |
| 0.042 | 0.149 | 0.107 | Fibroblast growth factor 1 antagonist | 0.107 0.052 DBMET02277 | DBMET02277 | |
| 0.017 | 0.126 | 0.029 | Toll-Like receptor 4 agonist | 0.029 0.013 DBMET03611 | DBMET03611 | |
| 0.04 | 0.151 | 0.059 | Gonadotropin-releasing hormone receptor agonist | 0.059 0.041 DBMET02277 | DBMET02277 | |
| 0.054 | 0.166 | 0.091 | Ferrochelatase inhibitor | 0.091 0.082 DBMET02278 | DBMET02278 | |
| 0.048 | 0.161 | 0.101 | Pim-1 kinase inhibitor | 0.101 0.057 DBMET02277 0.081 0.08 DBMET03609 | DBMET02277 | |
| 0.007 | 0.124 | 0.017 | O6-alkylguanine-DNA alkyltransferase inhibitor | 0.017 0.012 DBMET03611 | DBMET03611 | |
| 0.109 | 0.229 | 0.238 | Vasodilator | 0.238 0.077 DBMET03611 | DBMET03611 | |
| 0.104 | 0.225 | 0.211 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.211 0.083 DBMET02277 0.164 0.125 DBMET03609 | DBMET02277 | |
| 0.037 | 0.158 | 0.066 | MAP-kinase-activated kinase 2 inhibitor | 0.066 0.065 DBMET02277 | DBMET02277 | |
| 0.099 | 0.221 | 0.299 | Immunostimulant | 0.299 0.079 DBMET03611 | DBMET03611 | |
| 0.157 | 0.279 | 0.362 | Interleukin 2 agonist | 0.243 0.127 DBMET02277 0.362 0.04 DBMET03611 0.233 0.139 DBMET03609 0.276 0.092 DBMET02278 0.265 0.103 DBMET03608 | DBMET03611 | |
| 0.031 | 0.154 | 0.068 | Protein kinase C beta inhibitor | 0.068 0.052 DBMET03609 | DBMET03609 | |
| 0.066 | 0.189 | 0.137 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.102 0.101 DBMET02277 0.137 0.072 DBMET03609 | DBMET03609 | |
| 0.054 | 0.179 | 0.077 | MAP kinase kinase 7 inhibitor | 0.077 0.055 DBMET02277 | DBMET02277 | |
| 0.131 | 0.258 | 0.361 | Peptidyltransferase inhibitor | 0.18 0.129 DBMET03610 0.361 0.01 DBMET03611 0.197 0.103 DBMET03608 | DBMET03611 | |
| 0.14 | 0.268 | 0.178 | 5 Hydroxytryptamine 3E antagonist | 0.178 0.111 DBMET02278 | DBMET02278 | |
| 0.043 | 0.172 | 0.074 | MAP-kinase-activated kinase inhibitor | 0.074 0.071 DBMET02277 | DBMET02277 | |
| 0.135 | 0.267 | 0.22 | Vasodilator, peripheral | 0.22 0.154 DBMET03610 0.198 0.178 DBMET03611 | DBMET03610 | |
| 0.057 | 0.192 | 0.109 | Ribosomal protein S6 kinase inhibitor | 0.109 0.104 DBMET02277 | DBMET02277 | |
| 0.055 | 0.197 | 0.137 | AMP-activated protein kinase stimulant | 0.137 0.037 DBMET03611 | DBMET03611 | |
| 0.068 | 0.211 | 0.137 | CDC-like kinase 4 inhibitor | 0.137 0.112 DBMET02277 | DBMET02277 | |
| 0.117 | 0.26 | 0.27 | MAP-kinase-activated kinase 5 inhibitor | 0.173 0.144 DBMET03610 0.22 0.082 DBMET02277 0.27 0.047 DBMET03609 0.198 0.106 DBMET03608 | DBMET03609 | |
| 0.152 | 0.296 | 0.521 | Antibacterial | 0.521 0.035 DBMET03611 | DBMET03611 | |
| 0.032 | 0.178 | 0.06 | Heat shock protein 90 beta antagonist | 0.06 0.04 DBMET02277 | DBMET02277 | |
| 0.073 | 0.219 | 0.179 | TRKC antagonist | 0.179 0.079 DBMET02277 | DBMET02277 | |
| 0.03 | 0.178 | 0.059 | I kappa B kinase 2 inhibitor | 0.059 0.049 DBMET02277 | DBMET02277 | |
| 0.06 | 0.214 | 0.108 | Glutamate release inhibitor | 0.108 0.032 DBMET02277 | DBMET02277 | |
| 0.056 | 0.212 | 0.233 | Acetylcholinesterase inhibitor | 0.233 0.024 DBMET03611 | DBMET03611 | |
| 0.124 | 0.281 | 0.163 | MAP kinase kinase 5 inhibitor | 0.163 0.105 DBMET02277 0.153 0.142 DBMET03609 | DBMET02277 | |
| 0.051 | 0.212 | 0.117 | Alkylator | 0.117 0.071 DBMET03611 | DBMET03611 | |
| 0.072 | 0.236 | 0.124 | Protein kinase (CK1) gamma 3 inhibitor | 0.124 0.122 DBMET02277 | DBMET02277 | |
| 0.048 | 0.217 | 0.101 | NADH dehydrogenase inhibitor | 0.101 0.043 DBMET03611 0.079 0.077 DBMET03609 | DBMET03611 | |
| 0.075 | 0.246 | 0.138 | DNA methyltransferase I inhibitor | 0.138 0.118 DBMET03611 | DBMET03611 | |
| 0.047 | 0.218 | 0.115 | TRKA antagonist | 0.115 0.072 DBMET02277 | DBMET02277 | |
| 0.031 | 0.203 | 0.071 | Protein kinase B beta inhibitor | 0.071 0.055 DBMET03609 | DBMET03609 | |
| 0.08 | 0.253 | 0.178 | I kappa B kinase epsilon inhibitor | 0.178 0.091 DBMET02277 | DBMET02277 | |
| 0.123 | 0.298 | 0.351 | Antithrombotic | 0.351 0.064 DBMET03611 | DBMET03611 | |
| 0.049 | 0.223 | 0.169 | Amylase inhibitor | 0.169 0.056 DBMET03611 | DBMET03611 | |
| 0.138 | 0.313 | 0.266 | Histamine release inhibitor | 0.266 0.144 DBMET03611 0.203 0.199 DBMET02278 | DBMET03611 | |
| 0.06 | 0.252 | 0.183 | Cholinergic | 0.183 0.055 DBMET03611 | DBMET03611 | |
| 0.171 | 0.363 | 0.285 | 5 Hydroxytryptamine release inhibitor | 0.285 0.182 DBMET02278 | DBMET02278 | |
| 0.118 | 0.312 | 0.273 | Vasodilator, coronary | 0.273 0.111 DBMET03611 | DBMET03611 | |
| 0.067 | 0.272 | 0.145 | Hexokinase inhibitor | 0.145 0.085 DBMET03611 | DBMET03611 | |
| 0.05 | 0.259 | 0.207 | Protein kinase C nu inhibitor | 0.116 0.097 DBMET03610 0.207 0.045 DBMET03609 0.148 0.07 DBMET03608 | DBMET03609 | |
| 0.044 | 0.253 | 0.113 | Tyrosine-protein kinase receptor antagonist | 0.113 0.093 DBMET02277 | DBMET02277 | |
| 0.097 | 0.31 | 0.136 | CC chemokine 6 receptor antagonist | 0.136 0.05 DBMET03611 | DBMET03611 | |
| 0.069 | 0.288 | 0.179 | NOS3 expression enhancer | 0.179 0.051 DBMET03611 | DBMET03611 | |
| 0.062 | 0.282 | 0.123 | Aurora-C kinase inhibitor | 0.123 0.099 DBMET02278 | DBMET02278 | |
| 0.052 | 0.276 | 0.156 | EphB2 antagonist | 0.156 0.123 DBMET02278 | DBMET02278 | |
| 0.034 | 0.271 | 0.073 | Chymotrypsin inhibitor | 0.073 0.065 DBMET03609 | DBMET03609 | |
| 0.122 | 0.363 | 0.231 | Caspase 3 stimulant | 0.231 0.131 DBMET03611 | DBMET03611 | |
| 0.087 | 0.336 | 0.218 | Transcription factor NF kappa B inhibitor | 0.218 0.152 DBMET03611 | DBMET03611 | |
| 0.138 | 0.388 | 0.229 | MAP kinase kinase 3 inhibitor | 0.229 0.058 DBMET02277 0.217 0.08 DBMET03609 | DBMET02277 | |
| 0.091 | 0.347 | 0.226 | DNA synthesis inhibitor | 0.226 0.087 DBMET03611 | DBMET03611 | |
| 0.021 | 0.28 | 0.068 | Heparanase inhibitor | 0.068 0.013 DBMET03611 | DBMET03611 | |
| 0.039 | 0.309 | 0.088 | Electrolyte absorption antagonist | 0.088 0.078 DBMET03609 | DBMET03609 | |
| 0.06 | 0.335 | 0.35 | Free radical scavenger | 0.35 0.039 DBMET03611 | DBMET03611 | |
| 0.072 | 0.352 | 0.17 | Neurotrophic factor enhancer | 0.17 0.111 DBMET02277 | DBMET02277 | |
| 0.043 | 0.326 | 0.093 | Carbonic anhydrase XV inhibitor | 0.093 0.077 DBMET02277 | DBMET02277 | |
| 0.081 | 0.396 | 0.262 | Cholesterol antagonist | 0.262 0.117 DBMET03611 | DBMET03611 | |
| 0.031 | 0.347 | 0.163 | Thrombolytic | 0.163 0.072 DBMET03611 | DBMET03611 | |
| 0.092 | 0.455 | 0.306 | Apoptosis antagonist | 0.306 0.082 DBMET03611 | DBMET03611 | |
| 0.016 | 0.391 | 0.051 | Glucose-6-phosphate translocase inhibitor | 0.051 0.036 DBMET03611 | DBMET03611 | |
| 0.039 | 0.458 | 0.216 | Platelet adhesion inhibitor | 0.216 0.063 DBMET03611 | DBMET03611 | |
| 0.02 | 0.449 | 0.098 | Trypsin inhibitor | 0.098 0.018 DBMET03611 0.059 0.049 DBMET03609 | DBMET03611 | |
| 0.004 | 0.462 | 0.082 | Factor X inhibitor | 0.082 0.013 DBMET03611 | DBMET03611 | |
| 0.058 | 0.53 | 0.203 | Lipocortins synthesis antagonist | 0.202 0.055 DBMET02277 0.203 0.054 DBMET03609 | DBMET03609 | |
| 0.04 | 0.543 | 0.242 | Hepatoprotectant | 0.242 0.046 DBMET03611 | DBMET03611 | |
| 0.004 | 0.531 | 0.077 | Trypsin I inhibitor | 0.077 0.008 DBMET03611 | DBMET03611 | |
| 0.009 | 0.547 | 0.075 | Protein 50S ribosomal subunit inhibitor | 0.075 0.022 DBMET03611 | DBMET03611 | |
| 0.026 | 0.571 | 0.436 | Antioxidant | 0.176 0.136 DBMET03610 0.436 0.029 DBMET03611 0.167 0.145 DBMET03609 | DBMET03611 | |
| 0.03 | 0.591 | 0.097 | Toll-Like receptor 3 antagonist | 0.097 0.056 DBMET02277 | DBMET02277 | |
| 0.036 | 0.598 | 0.275 | Immunosuppressant | 0.275 0.131 DBMET03611 | DBMET03611 | |
| 0.004 | 0.612 | 0.091 | Antineoplastic antibiotic | 0.091 0.051 DBMET03611 | DBMET03611 | |
| 0.036 | 0.667 | 0.189 | Immunomodulator | 0.189 0.177 DBMET03611 | DBMET03611 | |
| 0.003 | 0.634 | 0.036 | 1,3-Beta-glucan synthase inhibitor | 0.033 0.008 DBMET03610 0.028 0.02 DBMET03611 0.036 0.006 DBMET03609 0.034 0.008 DBMET03608 | DBMET03609 | |
| 0.014 | 0.676 | 0.407 | Angiogenesis stimulant | 0.407 0.02 DBMET03611 | DBMET03611 | |
| 0.004 | 0.668 | 0.024 | Protein 30S ribosomal subunit inhibitor | 0.024 0.017 DBMET03611 | DBMET03611 | |
| 0.009 | 0.698 | 0.254 | Lipid peroxidase inhibitor | 0.152 0.067 DBMET03610 0.254 0.026 DBMET03611 0.155 0.065 DBMET03609 0.152 0.067 DBMET03608 | DBMET03611 | |
| 0.049 | 0.748 | 0.117 | Papain-like protease (SARS coronavirus) inhibitor | 0.117 0.09 DBMET02278 | DBMET02278 | |
| 0.004 | 0.719 | 0.198 | Selectin antagonist | 0.198 0.011 DBMET03611 | DBMET03611 | |
| 0.011 | 0.761 | 0.177 | Nitric oxide antagonist | 0.177 0.078 DBMET03611 | DBMET03611 | |
| 0.021 | 0.824 | 0.09 | Transcription factor NF kappa B stimulant | 0.09 0.05 DBMET03611 | DBMET03611 | |
| 0.019 | 0.832 | 0.332 | Antiinflammatory | 0.332 0.186 DBMET03611 | DBMET03611 | |
| 0.011 | 0.857 | 0.254 | Cyclophilin D inhibitor | 0.254 0.209 DBMET03611 | DBMET03611 | |
| 0.01 | 0.897 | 0.279 | Hypoglycemic | 0.279 0.061 DBMET03611 | DBMET03611 | |
| 0.005 | 0.927 | 0.053 | Antibiotic Aminoglycoside-like | 0.053 0.012 DBMET03611 | DBMET03611 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |